Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2016 | Research article

Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB

Authors: Yuanchao Li, Qin Zhang, Dandan Qi, Li Zhang, Lian Yi, Qianqian Li, Zhongling Zhang

Published in: The Journal of Headache and Pain | Issue 1/2015

Abstract

Background

As a complex nervous system disease, migraine causes severe healthy and social issues worldwide. Valproate (VPA) is a widely used treatment agent against seizures and bipolar disorder, and its function to alleviate damage due to migraine has also been verified in clinical investigations. However, the mechanism underlying the protective effect of VPA against migraine remains poorly revealed. In the current study, the major purpose was to uncover the mechanism which drove VPA to antagonize migraine.

Methods

Nitroglycerin (NTG) was employed to induce a migraine model in rats and the migraine animals were exposed to treatment of VPA of different doses. Thereafter, the levels of indicators related to oxidative stress were measured and used to evaluate the anti-oxidant potential of VPA. The expression of calcitonin gene-related peptide (CGRP) and c-Fos was also quantified with ELISA and immunohistochemistry, respectively. Western blotting and electrophoretic mobility shift assays (EMSA) were conducted to explore the effect of VPA treatment on NF-кB pathway.

Results

NTG induced the activation of oxidative stress and led to migraine in model animals, but pre-treatment with VPA attenuated the damage due to migraine attack in brain tissues. The level of lipid peroxidation was significantly reduced while the prodcution of anti-oxidant factors was restored. Furthermore, expressions of CGRP and c-Fos, which represented the neuronal activation, were also down-regulated by VPA. The results of western blotting and EMSA demonstrated that the above mentioned effect of VPA acted through the inhibition of NF-кB pathway.

Conclusions

Although controversies on the effect of VPA on NF-кB pathway existed, our study revealed an alternative mechanism of VPA in protecting against migraine, which would promote the development of therapeutic strategies of migraine.

Schurks M, Diener HC, Goadsby P (2008) Update on the prophylaxis of migraine. Curr Treat Option Ne 10(1):20–29CrossRef

Welch KM, Goadsby PJ (2002) Chronic daily headache: nosology and pathophysiology. Curr Opin Neurol 15(3):287–295CrossRefPubMed

Neeb L, Reuter U (2007) Nitric oxide in migraine. CNS Neurol Disord-Dr drug targets 6(4):258–264CrossRef

Sarchielli P, Alberti A, Russo S, Codini M, Panico R, Floridi A, Gallai V (1999) Nitric oxide pathway, Ca2+, and serotonin content in platelets from patients suffering from chronic daily headache. Cephalalgia 19(9):810–816CrossRefPubMed

Stepien A, Chalimoniuk M (1998) Level of nitric oxide-dependent cGMP in patients with migraine. Cephalalgia 18(9):631–634CrossRefPubMed

Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Therapeut 120(2):157–171CrossRef

Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G (2005) Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin‐induced Fos activation: studies in an animal model of migraine. Cephalalgia 25(8):612–621CrossRefPubMed

Knyihar-Csillik E, Toldi J, Mihaly A, Krisztin-Peva B, Chadaide Z, Nemeth H, Fenyo R, Vecsei L (2007) Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm (Vienna) 114(4):417–421. doi:10.1007/s00702-006-0545-z CrossRef

Wang S, Liu Z, Wang L, Zhang X (2009) NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 6(5):327–334. doi:10.1038/cmi.2009.43 CrossRefPubMedPubMedCentral

10.

Di W, Zheng ZY, Xiao ZJ, Qi WW, Shi XL, Luo N, Lin JW, Ding MH, Zhang AW, Fang YN (2015) Pregabalin alleviates the nitroglycerin-induced hyperalgesia in rats. Neuroscience 284:11–17. doi:10.1016/j.neuroscience.2014.08.056 CrossRefPubMed

11.

Yin Z, Fang Y, Ren L, Wang X, Zhang A, Lin J, Li X (2009) Atorvastatin attenuates NF-κB activation in trigeminal nucleus caudalis in a rat model of migraine. Neurosci Lett 465(1):61–65CrossRefPubMed

12.

Linde M, Mulleners WM, Chronicle EP, McCrory DC (2013) Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane DB Syst Rev 6:CD010611. doi:10.1002/14651858.CD010611

13.

Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, Wilson B, Lu RB, Gean PW, Chuang DM, Hong JS (2006) Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatr 11(12):1116–1125. doi:10.1038/sj.mp.4001893 CrossRef

14.

Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155(3):567–572CrossRefPubMedPubMedCentral

15.

Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp The 321(3):892–901. doi:10.1124/jpet.107.120188 CrossRef

16.

Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W, Wang K, Song W (2008) Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205(12):2781–2789. doi:10.1084/jem.20081588 CrossRefPubMedPubMedCentral

17.

Pardutz A, Hoyk Z, Varga H, Vecsei L, Schoenen J (2007) Oestrogen‐modulated increase of calmodulin‐dependent protein kinase II (CamKII) in rat spinal trigeminal nucleus after systemic nitroglycerin. Cephalalgia 27(1):46–53CrossRefPubMed

18.

Varga H, Pardutz A, Vamos E, Bohar Z, Bago F, Tajti J, Bari F, Vecsei L (2009) Selective inhibition of cyclooxygenase-2 attenuates nitroglycerin-induced calmodulin-dependent protein kinase II alpha in rat trigeminal nucleus caudalis. Neurosci Lett 451(2):170–173CrossRefPubMed

19.

Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez del Rio M, Letourneau R, Theoharides TC, Waeber C, Moskowitz MA (2001) Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 124(Pt 12):2490–2502CrossRefPubMed

20.

Erol I, Alehan F, Aldemir D, Ogus E (2010) Increased vulnerability to oxidative stress in pediatric migraine patients. Pediatr Neurol 43(1):21–24. doi:10.1016/j.pediatrneurol.2010.02.014 CrossRefPubMed

21.

Messlinger K, Lennerz JK, Eberhardt M, Fischer MJM (2012) CGRP and NO in the trigeminal system: mechanisms and role in headache generation. Headache 52(9):1411–1427CrossRefPubMed

22.

Placer ZA, Cushman L, Johnson BC (1966) Estimation of products of lipid peroxidation (malonyl dialdehyde) in biological fluids. Anal Biochem 16:359–364

23.

Desai ID (1984) Vitamin E analysis methods for animal tissues. Method Enzymol 105:138–147CrossRef

24.

Suzuki J, Katoh N (1990) A simple and cheap method for measuring vitamin A in cattle using only a spectrophotometer. The Japanese Journal of Veterinary Science 52:1282–1284

25.

Jagota SK, Dani HM (1982) A new colorimetric technique for the estimation of vitamin C using Folin phenol reagent. Anal Biochem 127(1):178–182CrossRefPubMed

26.

Fehrenbacher JC, Taylor CP, Vasko MR (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105(1-2):133–141CrossRefPubMed

27.

Offenhauser N, Zinck T, Hoffmann J, Schiemann K, Schuh‐Hofer S, Rohde W, Arnold G, Dirnagl U, Jansen‐Olesen I, Reuter U (2005) CGRP release and c‐fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 25(3):225–236CrossRefPubMed

28.

Team RC (2014) R (2012) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0

29.

Moskowitz MA (1992) Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13(8):307–311CrossRefPubMed

30.

Link AS, Kuris A, Edvinsson L (2008) Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 9(1):5–12. doi:10.1007/s10194-008-0011-4 CrossRefPubMedPubMedCentral

31.

Mattson MP (2005) NF-kappaB in the survival and plasticity of neurons. Neurochem Res 30(6-7):883–893. doi:10.1007/s11064-005-6961-x CrossRefPubMed

32.

Martinez-Cruz F, Osuna C, Guerrero JM (2006) Mitochondrial damage induced by fetal hyperphenylalaninemia in the rat brain and liver: its prevention by melatonin, Vitamin E, and Vitamin C. Neurosci Lett 392(1-2):1–4. doi:10.1016/j.neulet.2005.02.073 CrossRefPubMed

33.

Varoglu AO, Yildirim A, Aygul R, Gundogdu OL, Sahin YN (2010) Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance. Clin neuropharmacol 33(3):155–157CrossRefPubMed

34.

Wang JF, Azzam JE, Young LT (2003) Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 116(2):485–489CrossRefPubMed

35.

Zhang YJ, Zhang M, Wang XC, Yu YH, Jin PJ, Wang Y (2011) Effects of sodium valproate on neutrophils’ oxidative metabolism and oxidant status in children with idiopathic epilepsy. Zhonghua er ke za zhi Chinese Journal of pediatrics 49(10):776–781PubMed

36.

Taylor CP, Angelotti T, Fauman E (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel α 2–δ (alpha 2–delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73(2):137–150CrossRefPubMed

37.

Harris JA (1998) Using c-fos as a neural marker of pain. Brain Res Bull 45(1):1–8CrossRefPubMed

38.

Cutrer FM, Limmroth V, Ayata G, Moskowitz MA (1995) Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Brit J Pharmacol 116(8):3199–3204CrossRef

39.

Macdonald RL, Olsen RW (1994) GABAA receptor channels. Annu Rev Neurosci 17(1):569–602CrossRefPubMed

40.

Bonanno G, Raiteri M (1993) Multiple GABAB receptors. Trends Pharmacol Sci 14(7):259–261CrossRefPubMed

41.

Welch KM, Chabi E, Bartosh K, Achar VS, Meyer JS (1975) Cerebrospinal fluid gamma aminobutyric acid levels in migraine. Brit Med J 3(5982):516–517CrossRefPubMedPubMedCentral

42.

Cutrer FM, Limmroth V, Moskowitz MA (1997) Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 17(2):93–100CrossRefPubMed

43.

Morgan JI, Cohen DR, Hempstead JL, Curran T (1987) Mapping patterns of c-fos expression in the central nervous system after seizure. Science 237(4811):192–197CrossRefPubMed

44.

Meberg PJ, Kinney WR, Valcourt EG, Routtenberg A (1996) Gene expression of the transcription factor NF-κ B in hippocampus: regulation by synaptic activity. Molr Brain Res 38(2):179–190CrossRef

45.

Reuter U, Chiarugi A, Bolay H, Moskowitz MA (2002) Nuclear factor-κB as a molecular target for migraine therapy. Ann Neurol 51(4):507–516CrossRefPubMed

46.

Go HS, Seo JE, Kim KC, Han SM, Kim P, Kang YS, Han SH, Shin CY, Ko KH (2011) Valproic acid inhibits neural progenitor cell death by activation of NF-B signaling pathway and up-regulation of Bcl-XL. J Biomed Sci 18(1):48CrossRefPubMedPubMedCentral

47.

Rao JS, Bazinet RP, Rapoport SI, Lee HJ (2007) Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-κB DNA binding activity and COX‐2 mRNA1. Bipolar Disord 9(5):513–520CrossRefPubMed

48.

Wang Z, Leng Y, Tsai L-K, Leeds P, Chuang D-M (2011) Valproic acid attenuates blood–brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J Cerebr Blood F Met 31(1):52–57CrossRef

49.

Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, Fossati G, Moroni F, Chiarugi A (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Di 36(2):269–279CrossRef

50.

Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S (2000) Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB. Brain Res 857(1):246–251CrossRefPubMed

51.

Li Y, Yuan Z, Liu B, Sailhamer EA, Shults C, Velmahos GC, Alam HB (2008) Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition. J Trauma Acute Care 64(4):863–871CrossRef

Title: Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB
Authors: Yuanchao Li
Qin Zhang
Dandan Qi
Li Zhang
Lian Yi
Qianqian Li
Zhongling Zhang
Publication date: 01-12-2016
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-016-0631-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Valproate ameliorates nitroglycerin-induced migraine in trigeminal nucleus caudalis in rats through inhibition of NF-кB

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Autonomous control of cardiovascular reactivity in patients with episodic and chronic forms of migraine

Headache, depression and anxiety: associations in the Eurolight project

Altered functional connectivity of the marginal division in migraine: a resting-state fMRI study

High-flow oxygen therapy in cluster headache patients has no significant effect on nociception specific blink reflex parameters: a pilot study

Side-locked headaches: an algorithm-based approach

Age of onset of episodic and chronic cluster headache – a review of a large case series from a single headache centre